在患有肝炎相关抗原的患者中,瘤依赖性淋巴细胞功能.

A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C.

Hepatology (Baltimore, Md.)·1999

Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis.

Annals of internal medicine·1997

Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group.

Journal of viral hepatitis·1997

Management of haematemesis and melaena.

The Medical journal of Australia·1997

Treatment of cirrhotic hepatitis C virus patients with daily doses of interferon-alpha 2a.

Journal of viral hepatitis·1997

Chronic hepatitis C: effect of alcohol on hepatitic activity and viral titre.

Journal of hepatology·1996

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Dabrafenib-Induced Cutaneous Eruptions in a Patient With Langerhans Cell Histiocytosis.

Case reports in dermatological medicine·2026

Type 1 diabetes mellitus induced by sintilimab: a case report and related case literature analysis.

Frontiers in endocrinology·2026

Lipocalin-2 Emerges as a Core Pathogenic Mediator and Biomarker in Autosomal Dominant Tubulointerstitial Kidney Disease-UMOD via Transcriptomic Profiling.

Kidney diseases (Basel, Switzerland)·2026

Diffuse Large B-cell Lymphoma Initially Managed As Secondary Immune Thrombocytopenia: A Case Report.

Cureus·2026

Adverse pregnancy outcome associations among women prior to a diagnosis of systemic lupus erythematosus.

Frontiers in lupus·2026

Targeting TKT-associated immunometabolic remodeling attenuates experimental lupus nephritis and NET-related inflammation.

Frontiers in cell and developmental biology·2026

相关实验视频

在患有肝炎相关抗原的患者中,瘤依赖性淋巴细胞功能.

相关概念视频

A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C.

Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis.

Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group.

Management of haematemesis and melaena.

Treatment of cirrhotic hepatitis C virus patients with daily doses of interferon-alpha 2a.

Chronic hepatitis C: effect of alcohol on hepatitic activity and viral titre.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Dabrafenib-Induced Cutaneous Eruptions in a Patient With Langerhans Cell Histiocytosis.

Type 1 diabetes mellitus induced by sintilimab: a case report and related case literature analysis.

Lipocalin-2 Emerges as a Core Pathogenic Mediator and Biomarker in Autosomal Dominant Tubulointerstitial Kidney Disease-UMOD via Transcriptomic Profiling.

Diffuse Large B-cell Lymphoma Initially Managed As Secondary Immune Thrombocytopenia: A Case Report.

Adverse pregnancy outcome associations among women prior to a diagnosis of systemic lupus erythematosus.

Targeting TKT-associated immunometabolic remodeling attenuates experimental lupus nephritis and NET-related inflammation.

相关实验视频

在患有肝炎相关抗原的患者中,瘤依赖性淋巴细胞功能.

相关概念视频

相关文章